The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.
 
Salma K. Jabbour
Consulting or Advisory Role - IMX Medical Reviewer; Merck Sharp & Dohme; Syntactx
Research Funding - Merck Sharp & Dohme (Inst); NCI (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Ki Hyeong Lee
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer
 
Nicolaj Frost
Honoraria - AstraZeneca; BeiGene; Berlin-Chemie; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Pfizer; Roche Pharma AG; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Takeda
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Bristol-Myers Squibb; Lilly; Takeda
(OPTIONAL) Uncompensated Relationships - Deutsche Forschungsgemeinschaft
 
Valeriy Vladimirovich Breder
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Roche; Takeda
 
Dariusz M. Kowalski
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; MSD; Roche/Genentech
 
Issam Abdelkarim Alawin
No Relationships to Disclose
 
Evgeny Levchenko
Research Funding - AstraZeneca; AstraZeneca; BeiGene; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
 
Noemi Reguart
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Boehringer Ingelheim; Lilly; MSD Oncology; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; MSD; Roche; Roche Molecular Diagnostics
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - MSD; Roche
 
Alex Martinez-Marti
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche
 
Baerin Houghton
Consulting or Advisory Role - AstraZeneca; Merck
 
Jean-Baptiste Paoli
Research Funding - AstraZeneca; BMSi; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMSi; Boehringer Ingelheim; Eisai Europe; Fresenius Kabi; ipsen; Janssen-Cilag; MSD; Novartis/Ipsen; Pfizer; Pierre Fabre; Roche; Sanofi
 
Sufia Safina
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; JNJ; Lilly; LOXO; Merck KGaA; MSD; Ono Pharmaceutical; Puma Biotechnology
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology
 
Takefumi Komiya
Honoraria - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck
 
Amy Sanford
Research Funding - Lilly (Inst); Merck (Inst); NantWorks (Inst); QuantumLeap Health (Inst)
Travel, Accommodations, Expenses - Lilly (Inst)
 
Vishal Boolell
No Relationships to Disclose
 
Hong Liu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Ayman Samkari
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Steven M. Keller
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech